07-26-06

IFW

Express Mail Label No.: EV781047968US
Date of Deposit: July 25, 2006

Attorney Docket No: 24852-501 CIP5 NATL



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Bacopoulos *et al.*	CONF. NO.::	To Be Assigned
SERIAL NO.:	10/567,952	EXAMINER:	To Be Assigned
FILED:	February 10, 2006	ART UNIT:	To Be Assigned
FOR:	**METHODS OF TREATING CANCER WITH HDAC INHIBITORS**		

MAIL STOP AMENDMENT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (6 pages), in duplicate;
3. Cited References A1-A34; B1-B16; C1-C140; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. **50-0311** Ref. No. **24852-501 CIP5 NATL**. Please address all correspondence to Customer No. **35437**. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Dated: July 25, 2006

Michelle A. Klein

Ivor Elrifi, Reg. No. 39,529
Michelle A. Klein, Reg. No. 55,296
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Express Mail Label No.: EV781047968US
Date of Deposit: July 25, 2006

Attorney Docket No: 24852-501 CIP5 NATL



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Bacopoulos *et al.*	CONF. NO.::	To Be Assigned
SERIAL NO.:	10/567,952	EXAMINER:	To Be Assigned
FILED:	February 10, 2006	ART UNIT:	To Be Assigned
FOR:	**METHODS OF TREATING CANCER WITH HDAC INHIBITORS**		

MAIL STOP AMENDMENT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby makes of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. In accordance with MPEP §609(III)(A)(2), copies of the cited U.S. patents and U.S. publications are not required.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **24852-501 CIP5 NATL**, Customer No. **35437**.

Respectfully submitted,

Dated: July 25, 2006

Ivor Elrifi, Reg. No. 39,529
Michelle A. Klein, Reg. No. 55,296
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO P.C.
Chrysler Center
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Express Mail Label No.: EV781047968US
Date of Deposit: July 25, 2006

Please type a plus sign (+) in this box [+]



PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/567,952
	Filing Date	February 10, 2006
	First Named Inventor	Bacopoulos
	Group Art Unit / Conf. No.:	Not Yet Assigned / Not Yet Assigned
	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	24852-501 CIP5 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1*	5,055,608	10/08/91	Marks et al.			
	A2*	5,175,191	12/29/92	Marks et al.			
	A3*	5,369,108	11/29/94	Breslow et al.			
	A4*	5,608,108	03/04/97	Marks et al.			
	A5*	5,700,811	12/23/97	Breslow et al.			
	A6*	5,773,474	06/30/98	Breslow et al.			
	A7*	5,932,616	08/13/99	Breslow et al.			
	A8*	6,087,367	06/11/00	Breslow et al.			
	A9*	6,511,990	01/28/03	Breslow et al.			
	A10*	6,451,334	09/17/02	Perrine			
	A11*	2003/0161830	08/28/03	Jackson et al.			
	A12*	2004/0127523	07/01/04	Bacopoulos et al.			
	A13*	6,231,880	05/15/2001	Perrine			
	A14*	2004/0002506	12/30/2004	Breslow et al.			
	A15*	2004/0087631	05/06/2004	Bacopoulos et al.			
	A16*	2004/0122101	06/24/2004	Miller et al.			
	A17*	2004/0127522	07/01/2004	Chiao et al.			
	A18*	2004/0266818	01/01/2004	Breslow et al.			
	A19*	2004/0072735	04/15/2004	Richon et al.			
	A20*	2004/0132825	07/08/2004	Bacopoulos et			
	A21*	RE38,506 E	04/20/04	Breslow, et al.			
	A22*	2003/0082666	05/01/03	Kammer, et al.			
	A23*	2003/0235588	12/25/03	Richon, et al.			
	A24*	6,905,669	06/14/05	DiMartino			
	A25**	4,690,918	09/01/87	Beppu, et al.			
	A26**	5,654,333	08/05/97	The United States of America as represented by the Department of Health and Human Services			
	A27**	6,239,176	05/29/01	Beacon Laboratories, Inc. et al.			
	A28**	6,262,116	07/17/01	Sloan-Kettering Institute for Cancer Research			
	A29**	6,451,334	09/17/02	Perrine			
	A30**	6,495,719	12/17/02	CircaGen Pharmaceutical			
	A31**	2003/0114525	06/19/03	Kammer, et al.			
	A32**	2004/0132643	07/08/04	Fojo, et al.			
	A33**	2004/0167184	08/26/04	Wiech, et al.			
	A34	6,495,719	12/17/02	Lan-Hargest, et al.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes	No
	B1*	WO	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X	
	B2*	WO	00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X	
	B3*	WO	00/71703	Methylgene, Inc.	November 30, 2000	X	
	B4*	WO	01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X	
	B5*	WO	01/38322	Methylgene, Inc.	May 31, 2001	X	
	B6*	WO	01/70675	Methylgene, Inc.	September 27, 2001	X	
	B7*	WO	02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X	
	B8*	WO	02/30879	Prolifix Limited	April 18, 2002	X	
	B9*	WO	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X	
	B10*	WO	01/16106	Schering Aktiengesellschaft	03/08/2001	X	
	B11*	WO	95/31977	Sloan-Kettering Institute for Cancer Research	November 30, 1995	X	
	B12*	WO	98/55449	The University of Queensland	December 10, 1998	X	
	B13*	WO	02/085400	SuperGen, Inc.	October 31. 2002	X	
	B14**	WO	98/39965	Beacon Laboratories, LLC	09/17/98	X	
	B15**	WO	02/15921	The Government of the United States of America	02/28/02	X	
	B16**	WO	02/055017	Wake Forest University	07/18/02	X	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Andrews et al. (2000). *Intl. J. Parasitol.* 30: 761-768.
	C2*	Archer et al. (1998). *Proc. Natl. Acad. Sci. USA* 95: 6791-6796.
	C3*	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology, Abstract **4611**.
	C4*	Butler et al. (2000). *Cancer Res.* 60: 5165-5170.
	C5*	Butler et al. (2001). *Clincal Cancer Res.* 7: 962-970.
	C6*	Butler et al. (2002). *Proc. Natl. Acad. Sci. USA* 99: 11700-11705.
	C7*	Coffey et al. (2000). *Medical and Pediatric Oncology* 35: 577-581.
	C8*	Coffey et al. (2001). *Cancer Res.* 61: 3591-3594.
	C9*	Cohen et al. (1999). *Anticancer Res.* 19: 4999-5006.
	C10*	Cohen et al. (2002). *Anticancer Res.* 22: 1497-1504.
	C11*	Curtin (2002). *Exp. Opin. Ther. Patents* 12: 1375-1384.
	C12*	Dressel (2000). *Anticancer Res.* 20: 1017-1022.
	C13*	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology Abstract No. **4602**.
	C14*	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." *American Society of Hematology*, 44th Meeting of the American Society of Hematology, Abstract No. **3195**.
	C15*	Finnin et al. (1999). *Nature* 401: 188-193.
	C16*	Furamai et al. (2001). *Proc. Natl. Sci. USA* 98: 87-92.
	C17*	Grunstein (1997). *Nature* 389: 349-352.
	C18*	He et al. (2001). *J. Clin. Investigation* 108: 1321-1330.
	C19*	Hockly et al. (2003). *Proc. Natl. Acad. Sci. USA* 100: 2041-2046.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C20*	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." *American Society of Clinical Oncology,* Abstract No. **344**.
	C21*	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." *American Society of Clinical Oncology*, 38th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. **1831**.
	C22*	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." *European J. Cancer* 38(Suppl. 7): 88, Abstract No. **286**.
	C23*	Kim et al. (1999). *Oncogene* 18: 2461-2470.
	C24*	Kohge et al. (1998). *Biochem. Pharmacol.* 56: 1359-1364.
	C25*	Komatsu et al. (2001). *Cancer Res.* 61: 4459-4466.
	C26*	Kouraklis and Theocharis (2002). *Curr. Med. Chem.Anti-Cancer Agents* 2: 477-484.
	C27*	Lee et al. (2001). *Cancer Res.* 61: 931-934.
	C28*	Lin et al. (1998). *Nature* 391: 811-814.
	C29*	Mai et al. (2001). *OPPI Briefs* 33: 391-394
	C30*	Marks et al. (2000). *J. of the Natl. Cancer Institute* 92: 1210-1215.
	C31*	Marks et al. (2001). *Clinical Cancer Res.* 7: 759-760.
	C32*	Marks et al. (2001). *Curr. Opin. In Oncology* 13: 477-483.
	C33*	Marks et al. (2001). *Nature Reviews* 1: 194-202.
	C34*	Miller et al. (2003). *J Med Chem.* 46: 5097-5116.
	C35*	Munster et al. (2001). *Cancer Res.* 61: 8492-8497.
	C36*	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." *American Society of Clinical Oncology*, December 6-10, 2002, Abstract No. **4742.**
	C37*	Qui et al. (2000). *Mol. Biol. Cell* 11: 2069-2083.
	C38*	Richon et al. (1996). *Proc. Natl. Acad. Sci. USA* 93: 5705-5708.
	C39*	Richon et al. (1998). *Proc. Natl. Acad. Sci. USA* 95: 3003-3007.
	C40*	Richon et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 10014-10019.
	C41*	Richon and O'Brien (2002). *Clinical Cancer Res.* 8: 662-664.
	C42*	Saito et al. (1999). *Proc. Natl. Acad. Sci. USA* 96: 4592-4597.
	C43*	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and Radiation in Human Prostate Tumor Spheroids." *American Society of Clinical Oncology*, Abstract No. **105**.
	C44*	Stowell et al. (1995). *J. Med. Chem.* 38: 1411-1413.
	C45*	Su et al. (2000). *Cancer Res.* 60: 3137-3142.
	C46*	Suzuki et al. (1999). *J. Med. Chem.* 42: 3001-3003.
	C47*	Van Lint et al. (1996). *Gene Expression* 5: 245-253.
	C48*	Vrana et al. (1999). *Oncogene* 18: 7016-7025.
	C49*	Webb et al. (1999). *J. Biol. Chem.* 274: 14280-14287.
	C50*	Yoshida et al. (1990). *J. Biol. Chem.* 265: 17174-17179.
	C51*	Yoshida et al. (1995). *BioEssays* 17: 423-430.
	C52*	Zhou et al. (1999). *Gene* 233: 13-19.
	C53*	Zhou et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 1056-1061.
	C54*	Zhou et al. (2000). *Proc. Natl. Acad. Sci. USA* 97: 14329-14333.
	C55*	Zhou et al. (2001). *Proc. Natl. Acad. Sci. USA* 98: 10572-10577.
	C56*	International Search Report for PCT/US03/06451, mailed October 27, 2003
	C57*	International Preliminary Examination Report for PCT/US03/06451, mailed August 3, 2004
	C58*	International Search Report for PCT/US04/27943, mailed March 7, 2005
	C59*	Wu et al. (2001). "Negative Regulation of bcl-2 Expression by p53 in Hematopoietic Cells." Oncogene 20(2): 240-251, Abstract, Database CAPLUS on STN, Acc. No. DN134:293668.
	C60*	Adams and Elliott (2000). Oncogene 19: 6687-6692.
	C61*	Bates et al. (1999). Proc. American Society of Clinical Oncology 18: 180a, Abstract No. 693
	C62*	Foster et al. (1997). Invest. New Drugs 15: 187-194.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C63*	Gojo et al. (2002). Blood 100: Abstract No. 2198.
	C64*	Gore and Carducci (2000). Exp. Opin. Invest. Drugs 9: 2923-2934.
	C65*	Huang and Pardee (2000). Molecular Medicine 6: 849-866.
	C66*	Johnstone, R. (2002). Nature Reviews Drug Discovery 1: 287-299.
	C67*	Kelly et al. (2002). Exp. Opin. Invest. Drugs 11: 1695-1713.
	C68*	Kelly et al. (2002). Proc. American Society of Clinical Oncology 21: 6b, Abstract No. 1831.
	C69*	Kelly et al. (2001). Proc. American Society of Clinical Oncology 20: 87a, Abstract No. 344.
	C70*	Kosugi et al. (2001). Jpn. J. Cancer Res. 92: 529-536.
	C71*	Marshall et al. (2002). J. Exp. Therapeutics and Oncology 2: 325-332.
	C72*	Piekarz et al. (2001). Blood 98: 2865-2868.
	C73*	Prakash et al. (2001). Invest. New Drugs 19: 1-11.
	C74*	Rha et al. (1993). J. Korean Med. Sci. 8:251-256.
	C75*	Rifkind et al. (2002). 224th ACS National Meeting, Boston, MA, Abstract No. 226.
	C76*	Sandor et al. (2002). Clincal Cancer Research 8: 718-728.
	C77*	Secrist et al. (2003). Curr. Opin. Invest. Drugs 4:1422-1427.
	C78*	Summerhayes, M. (2001). J. Oncol. Pharm. Prac. 7: 107-125.
	C79*	Vigushin, D. (2002). Current Opin. Invest. Drugs 3: 1396-1402.
	C80*	Warrell et al. (1998). J. Natl. Cancer Institute 90: 1621-1625.
	C81*	O'Connor et al. (2001). Journal of the American Society of Hematology 611a, Abstract No. 2562.
	C82*	Kelly, et al. (2003). Clinical Cancer Research 9:3578-3588.
	C83**	Cao et al.(2001). Am. J. Respir. Cell Mol. Biol., 25:562-8.
	C84**	Waheed et al. (2000). Proceedings of the American Association for Cancer Research, 41:808.
	C85**	Weiser et al. (2001). J. Immunother., 24:151-61
	C86**	"Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA", October 30, 2002.
	C87**	"Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias", July 1, 2003.
	C88**	"Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President, Oncology Clinical Research and Development", September 20, 2002.
	C89**	"Aton Pharma, Inc. Presents Phase I Trial Data of Anti-Cancer Agent SAHA in Patients with hematological Malignancy at ASCO", June 2, 2003.
	C90**	"Aton Pharma, Inc. Presents Phase I Trial Data on Anti-Cancer Agent SAHA at EORTC/NCI/AACR Symposium", November 21, 2002.
	C91**	"Aton Pharma, Inc. Received Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I Trial", October 13, 2003.
	C92**	"Aton Pharma, Inc. Reports on Phase I Trial of SAHA", August 14, 2002.
	C93**	Adhikari, D et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1998), Vol. 39, p 312, "Radiosensitization of Lymphoma Cell Lines by Sodium Butyrate".
	C94**	Alexandrov, I et al., FEBS Letters, (1998), Vol. 434, pp 209-214, "Sodium Butyrate Suppresses Apoptosis in Human Burkitt Lymphomas and Murine Plasmacytomas Bearing c-myc Translocations".
	C95**	Almenara, J et al., Leukemia (2002), Vol. 16, pp 1331-1343, "Synergistic Induction of Mitochondrial Damage and Apoptosis in Human Leukemia Cells by Flavopiridol and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA)".
	C96**	Amin HM et al., British Journal of Haematology (2001), Vol. 115, pp 287-297, "Histone Deacetylase Inhibitors Induce Caspase-Dependent Apoptosis and Downregulation of Daxx in Acute Promyelocytic Leukaemia with t(15;17)".
	C97**	Aron, JL et al., Blood (2003), Vol. 102, No. 2, pp 652-658, "Depsipeptide (FR901228) Induces Histone Acetylation and Inhibition of Histone Deacetylase in Chronic Lymphocytic Leukemia Cells Concurrent With Activation of Caspase 8-mediated Apoptosis and Down-Regulation of c-FLIP Protein".
	C98**	Benoit, NE et al., Immunopharmacology, (1996), Vol. 35, pp 129-139, "Increased inhibition of Proliferation of Human B Cell Lymphomas Following Litigation of CD40, and Either CD19, CD20, CD95 or Surface Immunoglobulin".
	C99**	Bode, J et al., Journal of Interferon Research, (1982), Vol. 2, No. 2, pp 159-166, "Links Between Effectsof Butyrate on Histone Hyperacetylation and Regulation of interferon Synthesis in Namalva and FS-4 Cell Lines".
	C100**	Buckley, AR et al., Cell Growth & Differentiation (1996), Vol. 7, pp 1713-1721, "Alterations in pim-1 and c-myc

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		Expression Associated with Sodium Butyrate-induced Growth Factor Dependency in Autonomous Rat Nb2 Lymphoma Cells".
	C101**	Buckley, AR et al., Proceedings of the American Association for Cancer Research Annual Meeting, (1997), Vol. 38, p 193, "Reversal of Apoptosis Resistance by Butyrate in rat Nb2 Lymphoma Cells".
	C102**	Byrd, JC et al., Blood (1999), Vol. 94, No. 4, pp 1401-1408, "Depsipeptide (FR901228): A Novel Therapeutic Agent with Selective, In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells".
	C103**	Carducci, MA et al., Clinical Cancer Research (2001), Vol. 7, No. 10, pp 3047-3055, "A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule".
	C104**	Dear, AE et al., Biochimica et Biophysics Acta, (2000), Vol. 1492, pp 15-22, "The Novel Anti-Tumour Agent Oxamflatin Differentially Regulates Urokinase and Plasminogen Activator Inhibitor Type 2 Expression and Inhibits Urokinase-Mediated Proteolytic Activity".
	C105**	Desai, D et al., Anticancer Research (2003), Vol. 23, pp 499-504, "Chemopreventive Efficacy of Suberoylanilide Hydroxamic Acid (SAHA) Against 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced Lung Tumorigenesis in Female A/J Mice".
	C106**	Dhordain, P et al., Nucleic Acids Research, (1998), Vol. 26, No. 20, pp 4645-4651, "The LAZ3(BCL-6) Oncoprotein Recruits a SMRT/mSIN3A/Histone Deacetylase Containing Complex to Mediate Transcriptional Repression".
	C107**	Edelman, MJ et al., Cancer Chemotherapy and Pharmacology (2003), Vol. 51, pp 439-444, "Clinical and Pharmacologic Study of Tributyrin: An Oral Butyrate Prodrug".
	C108**	Feinman, R et al., Blood (2002), Vol. 100, No. 11, pp Abstract 3195, "The Histone Deacetylast Inhibitor, Suberoylanilide Hydroxyamic Acid, Induces Apoptosis of Multiple Myeloma Cells".
	C109**	Fillppovich, I et al., Biochemical and Biophysical Research Communications, (1994), Vol. 198, pp 257-265, "Butyrate Induced Apoptosis in Lymphoid Cells Preceded by Transient Over-Expression of HSP70 mRNA".
	C110**	Foss, FM et al., Blood, (1993), Vol. 82, No. 10, Suppl. 1, p 564A, "Biomodulatory Effects of Butyric Acid Derivatives on Leukemia and Lymphoma Cells".
	C111**	Gelmetti, V et al., Molecular and Cellular Biology (1998), Vol. 18, No. 12, pp 7185-7191, "Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO".
	C112**	Gerbitz, A, Oncogene, (1999), Vol. 18, pp 1745-1753, "Deregulation of the Proto-Oncogene c-myc Through t(8;22) Translocation in Burkitt's Lymphoma".
	C113**	Gilbert, J et al., Clinical Cancer Research (2001), Vol. 7, No. 8, pp 2292-2300, "A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies".
	C114**	Grisolano, JL et al., Proceedings of the National Academy of Sciences (2003), Vol. 100, No. 16, pp 9506-9511, "An Activated Receptor Tyrosine Kinase, TEL/PDGFbetaR, Cooperates with AML1/ETO to Induce Acute Myeloid Leukemia in Mice".
	C115**	Harris, NL et al., Blood (1994), Vol. 84, No. 5, pp 1361-1392, "A Revised European-American Classification of Lymphold Neoplasms: A Proposal From the International Lymphoma Study Group".
	C116**	Jaboin, J et al., Cancer Research (2002), Vol. 62, No. 21, pp 6108-6115, "MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors".
	C117**	Kurita-Ochiai, T et al., Infection and Immunity, (1998), Vol. 66, No. 6, pp 2587-2594, "Volatile Fatty Acid, Metabolic By-Product of Periodontopathic Bacteria, Induces Apoptosis in WEHI 231 and RAJI B Lymphoma Cells and Splenic B Cells".
	C118**	Liu, Z et al., Journal of Cancer Research and Clinical Oncology, (1998), Vol. 124, pp 541-548, "Synergistic Effect of Epstein-Barr Virus and Tumor Promoters on Induction of Lymphoma and Carcinoma in Nude Mice".
	C119**	Madisen, L et al., Molecular and Cellular Biology, (1998), Vol. 18, No. 11, pp 6281-6292, "The Immunoglobulin Heavy Chain Locus Control Region Increases Histone Acetylation along Linked c-myc Genes".
	C120**	Niitsu, N et al., Molecular Pharmacology, (2000), Vol. 58, pp 27-36, "Anticancer Derivative of Butyric Acid (Pivalyloxymethyl Butyrate) Specifically Potentiates the Cytotoxicity of Doxorubicin and Daunorubicin Through the Suppression of Microsomal Glycosidic Activity".
	C121**	Orr, D et al., 2000 ASCO Annual Meeting, Abstract No. 763, "Phase I Pharmacokinetic (PK) Study of CI-994 in Combination with Gemcitabine (GEM) in Patients with Advanced Solid Tumors".
	C122**	Polack, A et al., The EMBO Journal, (1993), Vol. 12, No. 10, pp 3913-3920, "Regulatory Elements in the Immunoglobulin Kappa Locus Induce c-myc Activation and the Promoter Shift in Burkitt's Lymphoma Cells".
	C123**	Rezuke, WN et al., Clinical Chemistry (1997), Vol. 43, No. 10, pp 1814-1823, "Molecular Diagnosis of B- and T-cell Lymphomas: Fundamental Principles and Clinical Applications".
	C124**	Rottleb, C et al., International Journal of Cancer, (1995), Vol. 62, pp 697-702, "Among 17 Inducers of Differentiation Only Sodium Butyrate Causes a Permanent Down-Regulation of c-myc in Burkitt's Lymphoma".

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C125**	Rottleb, C et al., International Journal of Cancer, (1996), Vol. 67, pp 724-729, "Structure-Activity Relationship of 17 Structural Analogues of N-Butyric Acid Upon .c-myc Expression".
	C126**	Rubio, MA et al., Blood, (1995), Vol. 86, No. 10, pp 3715-3724, "Granulocyte-Macrophase Colony-Stimulating Factor, Phorbol Ester, and Sodium Butyrate Induce the CD11c Integrin Gene Promoter Activity During Myeloid Cell Differentiation".
	C127**	Schrump, DS et al., Clinical Lung Cancer (2002), Vol. 4, No. 3, pp 186-192, "Phase I Study of Sequential Deoxyazacytidine/depsipeptide Infusion in Patients with Malignancies Involving Lungs or Pleura".
	C128**	Vrana JA et al., Oncogene 1999), Vol. 18, pp 7016-7025, "Inductiono f Apoptosis in U937 Human Leukemia Cells by Suberoylanilide Hydroxamic Acid (SAHA) Proceeds Through Pathways That are Regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53".
	C129**	Watanabe, M et al., Cancer Research (1990), Vol. 50, pp 3245-3248, "Effect of liposomes containing sodium butyrate conjugated with anti-CD19 monoclonal antibody on in vitro and in vivo growth of malignant lymphoma".
	C130**	Yu, C et al., Cancer Research (2001), Vol. 63, pp 2118-2126, "Histone Deacetylase Inhibitors Promote STI571-Mediated Apoptosis in STI571-Sensitive and –Resistant Bcr/Abl+ Human Myeloid Leukemia Cells".
	C131**	Zhang, M et al., Cell Stress & Chaperones, (1998), Vol 3, No. 1, pp 57-66, "Heat-Induced Proteolysis of HSF Causes Premature Deactivation of the Heat Shock Response in Nb2 Lymphoma Cells".
	C132	Gediya, et al., J. Med. Chem., (2005), Vol. 48, pp 5047-5051, "A New Simple and High-Yield Synthesis of Suberoylanilide Hydroxamic Acid and Its Inhibitory Effect Alone or in Combination with Retinoids on Proliferation of Human Prostate Cancer Cells".
	C133	Bruner, RJ et al., Blood (2002), 44th Annual Meeting of the American Society of Hematology, Vol. 100, No. 11, pp Abstract No. 1492, "Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in fludarabine refractory chronic lymphocytic leukemia".
	C134	Guo, F et al., American Society of Hematology, (December 6-10, 2002), p 268b, Abstract 4602 "Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Apo-2L/TRAIL-induced death inducing signaling complex and apoptosis of human acute lymphoid leukemia cells".
	C135	Heaney, M et al., 2003 ASCO Annual Meeting, Proceedings of the American Society of Clinical Oncology, (2003) Vol. 22, p 577, Abstract 2321, "Clinical experience with the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with hematological malignancies".
	C136	Marcucci, G et al., Blood, (2002), 44th Annual Meeting of the American Society of Hematology", Vol. 100, No. 11, pp Abstract No. 317, "Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in acute myeloid leukemia (AML)".
	C137	Nimmanapalli, R et al., American Society of Hematology, (December 6-10, 2002), 14 pages, "Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevee-induced apoptosis of Ber-Abl positive human acute leukemia cells".
	C138	Nimmanapalli, R et al., Blood (2003), Vol. 101, No. 8, pp 3236-3239, "Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells".
	C139	Tabe, Y et al., Blood (2002), 44th Annual Meeting of the American Society of Hematology, Vol. 100, No. 11, pp Abstract No. 3028, "Effects of histone deacetylase inhibitor suberoylanikide hydroxamic acid (SAHA) and DNA methylation inhibitor 5-aza-2'-deoxycytidine (DAC) on the transcriptional activation of RARbeta and p21WAF in acute promyelocytic leukemia cells".
	C140	Zhang, C et al, The Journal of Investigative Dermatology (2003), Vol. 121, No. 1, pp Abstract 1189, "The histone inhibitor suberoylanilide hydroxamic acid induces apoptosis in cutaneous T cell lymphoma cells".

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. **10/379,149**, filed **March 4, 2003**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. **10/650,025, filed **August 26, 2003**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.